Performance evaluation of two methods using commercially available reagents for PCR-based detection of FMR1 mutation
Jane S Juusola1, Paula Anderson, Fernanda Sabato
1Division of Molecular Diagnostics, Department of Pathology, Molecular Diagnostics Laboratory, Virginia Commonwealth University, Richmond, Virginia 23298-0248, USA.
The Journal of Molecular Diagnostics : JMD
|July 7, 2012
Summary
New PCR-based Fragile X (FMR1) testing methods simplify workflows and improve mosaicism detection. Both Asuragen and Abbott Molecular reagents showed high accuracy, with Asuragen offering superior sensitivity for low-level mosaicism.
Area of Science:
- Genetics
- Molecular Biology
- Clinical Diagnostics
Background:
- The traditional clinical workflow for Fragile X testing is inefficient and labor-intensive.
- Polymerase Chain Reaction (PCR)-based methods offer a streamlined approach for Fragile X testing.
- These PCR methods enhance the amplification of full mutation alleles and improve the detection of low-level mosaicism.
Purpose of the Study:
- To evaluate the performance characteristics and workflow of two commercially available PCR-based methods for Fragile X gene (FMR1) mutation status determination.
- To assess the sensitivity of these methods in detecting varying levels of mosaicism in both males and females.
Main Methods:
- Two PCR-based methods were evaluated: Asuragen AmplideX FMR1 PCR (research use only) and Abbott Molecular analyte-specific reagents (FMR1 Primer 1 and Primer 2).
- Performance was assessed through accuracy, precision, correlation with previous results, and workflow analysis.
- Mosaicism detection was tested across a range of 1% to 50% (females) and 1% to 100% (males).
Main Results:
- Both methods demonstrated equal performance in accuracy and precision using NIST standards and Coriell samples.
- A 100% concordance was observed between both methods and previous consensus study results, as well as with previously analyzed patient samples.
- Asuragen reagents detected mosaicism down to 5% (full mutation) and 1% (premutation), while Abbott Molecular Primer 2 detected mosaicism down to 25% for both mutation types.
Conclusions:
- Both evaluated PCR-based methods are accurate and precise for determining FMR1 mutation status.
- The primary difference between the two methods lies in their workflow efficiency.
- Asuragen reagents exhibited superior sensitivity in detecting low-level mosaicism compared to Abbott Molecular reagents.
